Evidence map›Paper›PMID 27475861›Full record

ArticleToxicon : official journal of the International Society on Toxinology2016

Gambierol and n-alkanols inhibit Shaker Kv channel via distinct binding sites outside the K(+) pore.

Evelyn Martínez-Morales, Ivan Kopljar, Jon D Rainier, Jan Tytgat, Dirk J Snyders, Alain J Labro

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Toxicon : official journal of the International Society on Toxinology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Evelyn Martínez-MoralesDepartment of Biomedical Sciences, University of Antwerp, 2610 Antwerp, Belgium.
Ivan KopljarDepartment of Biomedical Sciences, University of Antwerp, 2610 Antwerp, Belgium.
Jon D RainierDepartment of Chemistry, University of Utah, 315 South 1400 East, Salt Lake City, UT 84112-0850, USA.
Jan TytgatToxicology & Pharmacology, Campus Gasthuisberg, Onderwijs en Navorsing 2, Herestraat 49, bus 922, KULeuven, B-3000, Belgium.
Dirk J SnydersDepartment of Biomedical Sciences, University of Antwerp, 2610 Antwerp, Belgium.
Alain J LabroDepartment of Biomedical Sciences, University of Antwerp, 2610 Antwerp, Belgium. Electronic address: alain.labro@uantwerpen.be.
University of Antwerp · BEKU Leuven · BEUniversity of Utah · US

Funding

FUNGICIDAL AND NEUROTOXIC MARINE NATURAL PRODUCTSR01GM056677 · NIGMS · UNIVERSITY OF UTAH · PI RAINIER, JON DOUGLAS · 1998 to 2010
$2.5M
NIGMS NIH HHS R01 GM056677
6 · The paper itself

Abstract

The marine polycyclic-ether toxin gambierol and 1-butanol (n-alkanol) inhibit Shaker-type Kv channels by interfering with the gating machinery. Competition experiments indicated that both compounds do not share an overlapping binding site but gambierol is able to affect 1-butanol affinity for Shaker through an allosteric effect. Furthermore, the Shaker-P475A mutant, which inverses 1-butanol effect, is inhibited by gambierol with nM affinity. Thus, gambierol and 1-butanol inhibit Shaker-type Kv channels via distinct parts of the gating machinery.

Indexed as

1-ButanolBinding SitesCiguatoxinsIon Channel GatingOxocinsPotassium Channel BlockersShaker Superfamily of Potassium Channels1-ButanolCiguatoxinsgambierolOxocinsPotassium Channel BlockersShaker Superfamily of Potassium Channels1-AlcoholElectrophysiologyGating modifierLipophilic marine toxinPotassium channel

Identifiers

PMID27475861
PMCPMC7008702
OpenAlexW2499631606

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.